We defended Novartis Consumer Health against claims of renal failure from the use of a pharmaceutical product. We were able to show that the Plaintiff had abused the use of the product and was a seeker of prescription pain pills from multiple doctors, all of which caused or contributed to any injury she suffered.
Defense of Novartis Consumer Health
You Also May Be Interested In:
Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.
Represented Boston Children’s Hospital with intellectual property, business, and government contracting issues associated with VaccineFinder